GCVRZ - Sanofi CONTGNT VAL RT

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.52
-0.02 (-3.70%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.54
Open0.54
Bid0.52 x 1000
Ask2.40 x 2200
Day's Range0.52 - 0.55
52 Week Range0.34 - 0.60
Volume102,989
Avg. Volume121,025
Market Cap652.99M
Beta0.57
PE Ratio (TTM)0.06
EPS (TTM)8.18
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
    Market Realist5 days ago

    Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018

    GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.

  • Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
    Market Realist5 days ago

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist6 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...

  • Analyzing GlaxoSmithKline’s Revenue Trends
    Market Realist6 days ago

    Analyzing GlaxoSmithKline’s Revenue Trends

    In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.

  • Novo Nordisk: A Financial Overview after the First Half of 2018
    Market Realist6 days ago

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.

  • In $270M Peninsula vaccine company buyout, small players look to be big shots
    American City Business Journals9 days ago

    In $270M Peninsula vaccine company buyout, small players look to be big shots

    A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.

  • What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
    Market Realist9 days ago

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

  • Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
    Market Realist10 days ago

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.

  • Regeneron Stock Up 7% on Strong Q2 2018 Results
    Market Realist16 days ago

    Regeneron Stock Up 7% on Strong Q2 2018 Results

    On August 2, Regeneron Pharmaceuticals (REGN) posted earnings results for its fiscal second quarter of 2018, which ended on June 30. It posted strong results and raised its fiscal 2018 guidance. It registered strong sales and earnings while achieving significant product pipeline milestones.

  • Eli Lilly’s Q2 2018 Earnings: New Products
    Market Realist16 days ago

    Eli Lilly’s Q2 2018 Earnings: New Products

    Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.

  • Investor's Business Daily17 days ago

    Can Regeneron Stock Hit $400 For The First Time This Year?

    Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.

  • Sanofi’s Q2 2018 Earnings: Sales and Profits Decline
    Market Realist19 days ago

    Sanofi’s Q2 2018 Earnings: Sales and Profits Decline

    Today, Sanofi (SNY) reported its Q2 2018 results before the market opened. The sales in the quarter were up ~0.1% at CER (constant exchange rate) and down ~2.5% at a CER/CS (constant structure), adjusting for the Bioverativ acquisition. SNY stock is trending higher today after the earnings release.

  • Wall Street Analysts Estimate a Decline in Sanofi’s Adjusted EPS in Q2
    Market Realist24 days ago

    Wall Street Analysts Estimate a Decline in Sanofi’s Adjusted EPS in Q2

    Sanofi (SNY) is one of the global pharmaceuticals majors in the world and is headquartered in Paris. It’s expected to announce its Q2 2018 earnings results on July 31. According to Wall Street analysts’ estimates, Sanofi could register adjusted diluted EPS of 1.22 euros in Q2 2018, representing a decline of ~10% YoY (year-over-year).

  • Could Sanofi’s Sales Decline Again in Q2 2018?
    Market Realist24 days ago

    Could Sanofi’s Sales Decline Again in Q2 2018?

    Sanofi (SNY) is expected to release its Q2 2018 earnings on July 31. Analysts expect SNY to report sales of 8.4 billion euros in Q2 2018, representing a YoY (year-over-year) growth of ~3.6%. Sanofi had sales of 7.9 billion euros in Q1 2018, which represented a YoY decline of ~8.7%.

  • Analysts’ Recommendations for Sanofi Stock before Q2 Results
    Market Realist24 days ago

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases. As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.

  • Sanofi's venture arm backs 'digital' drug startup Click Therapeutics
    American City Business Journals27 days ago

    Sanofi's venture arm backs 'digital' drug startup Click Therapeutics

    Click plans to seek FDA approval for its "digital therapeutics" as a type of medical device, allowing them to be prescribed by physicians and reimbursed by insurers.

  • Novartis’s Innovative Medicines Segment in Q2 2018
    Market Realist27 days ago

    Novartis’s Innovative Medicines Segment in Q2 2018

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The segment contributed 67.4% of Novartis’s total revenues in the second quarter and reported a 10% growth YoY (year-over-year) at $8.9 billion.